文献速递乳腺癌

他莫昔芬与芳香化酶抑制剂在绝经后早期乳腺癌患者中新发脂肪肝风险及血脂变化的不同模式:倾向评分匹配队列研究

Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study.
PubMed 文献 · Eur J Cancer · 2017-06-23

该研究在1203例基线无脂肪肝、接受他莫昔芬(TMX)或芳香化酶抑制剂(AI,阿那曲唑或来曲唑)辅助内分泌治疗的受试者中按倾向评分1:1匹配,比较新发脂肪肝风险及血脂纵向变化。匹配后328例受试者共987.4人年随访中,TMX组新发脂肪肝62例、AI组41例。

要点

  • TMX组脂肪肝发病率高于AI组(每1000人年128.7 vs 81.1,P=0.021),尤其在治疗前2年内。
  • TMX与新发脂肪肝5年风险升高相关(校正风险比1.61,P=0.030),独立于肥胖和胆固醇水平。
  • 发生脂肪肝者基线甘油三酯较高、高密度脂蛋白胆固醇较低,随访期间持续存在。

核心结论

  • 在绝经后早期乳腺癌患者中,TMX较AI独立增加新发脂肪肝的5年风险。
  • 作者认为应将脂肪肝风险视为AI与TMX不同的不良事件特征,尤其在肥胖、高甘油三酯和低HDL-C的患者中。

研究设计与样本

  • 研究纳入1203例基线无脂肪肝、接受辅助TMX或AI(阿那曲唑或来曲唑)治疗的受试者,按倾向评分1:1匹配。
  • 匹配后共328例受试者(平均年龄53.5岁,体重指数22.9 kg/m2),总随访987.4人年。
  • 主要结局为每年肝脏超声检出的新发脂肪肝。

主要发现

  • TMX组检出脂肪肝62例,AI组41例。
  • TMX组脂肪肝发病率高于AI组(每1000人年128.7 vs 81.1,P=0.021),尤其在治疗前2年内。
  • TMX与新发脂肪肝5年风险升高相关(校正风险比1.61,P=0.030),独立于肥胖和胆固醇水平。
  • 发生脂肪肝者基线甘油三酯较高、高密度脂蛋白胆固醇较低,随访期间持续存在,尽管TMX有降低血清胆固醇的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Management of metabolic complications of long-term adjuvant endocrine therapy in early breast cancer remained an unmet need. We aimed to compare the effects of tamoxifen (TMX) and aromatase inhibitors (AIs) on the risk of fatty liver in conjunction with longitudinal changes in the serum lipid parameters. METHODS: Among 1203 subjects who were taking adjuvant TMX or AI (anastrozole or letrozole) without fatty liver at baseline, those taking TMX or AI were 1:1 matched on the propensity score. The primary outcome was newly developed fatty liver detected on annual liver ultrasonography. RESULTS: Among 328 matched subjects (mean age 53.5 years, body mass index 22.9 kg/m2), 62 cases of fatty liver in the TMX group and 41 cases in the AI group were detected in a total of 987.4 person-years. The incidence rate of fatty liver was higher in the TMX group than in the AI group (128.7 versus 81.1 per 1000 person-years, P = 0.021), particularly within the first 2 years of therapy. TMX was associated with an increased 5-year risk of newly developed fatty liver (adjusted hazard ratio 1.61, P = 0.030) compared with AI independent of obesity and cholesterol level. Subjects who developed fatty liver had higher triglycerides (TGs) and lower high-density lipoprotein cholesterol (HDL-C) level at baseline than those without, which was sustained during follow-up despite the serum cholesterol-lowering effect of TMX. CONCLUSIONS: TMX independently increased the 5-year risk of newly developed fatty liver compared with AI in postmenopausal women with early breast cancer. Our findings suggest the need for considering the risk of fatty liver as a different adverse event profile between AI and TMX, particularly in patients with obesity, high TGs and low HDL-C.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Hong N, Yoon HG, Seo DH, et al. Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study. Eur J Cancer. 2017. PMID: 28651157. doi:10.1016/j.ejca.2017.05.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。